ClinicalTrials.gg
Not yet recruitingNCT07926789Updated Nov 9, 2026

Neuromuscular Taping on Muscle Pain in Patients With Degenerative Osteoarticular Disease of the Spine

An interventional study of kinesio taping and sham kinesiotaping in Cervicalgia and Back Pain, Low, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Treatment

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if neuromuscular taping (kinesio taping), added to a standard exercise program, reduces muscle pain in adults with chronic neck pain or chronic low back pain caused by degenerative disease of the spine (such as facet joint osteoarthritis, spondylosis, or degenerative disc disease). The main questions it aims to answer are:

Does neuromuscular taping, applied once a week for 3 weeks in addition to standard exercise therapy, reduce muscle pain more than placebo taping?

Researchers will compare neuromuscular taping applied with a muscle and fascial technique to placebo taping (the same tape placed on the same area without tension or therapeutic technique) to see if the active taping provides greater pain relief.

02

Conditions studied

  • Cervicalgia
  • Back Pain, Low
03

In context

Neck Pain

1,360 studies on the registry are indexed under Neck Pain; 299 are open to participants now.

This study's planned enrollment of 500 is above the median of 50 across 1,116 interventional studies indexed under Neck Pain.

Browse Neck Pain studies →

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 41 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older
  • Persistent pain (duration of more than 3 months) with a diagnosis of chronic -neck pain or chronic low back pain due to degenerative joint disease
  • Stable pain treatment, with no changes expected during the following 3 weeks
  • Willingness to participate and signed

Exclusion criteria

Exclusion Criteria:

  • Cervicobrachialgia (neck pain radiating to the arm)
  • Lumbosciatica (low back pain radiating to the leg)
  • Pregnancy in the second or third trimester
  • Skin conditions that contraindicate the application of neuromuscular tape
  • Allergy to adhesive materials
  • Thrombosis or risk of thrombosis
  • Severe trauma that has not been previously examined and diagnosed by a physician
  • Participation in another clinical trial involving an experimental intervention during the period of this trial and/or with a visit schedule incompatible with this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will have neuromuscular tape applied to the neck or lower back after the first exercise session of each week, and remove it on the fourth day

    Device: kinesio taping

  • Sham comparator
    Control

    These patients will have the same tape placed on the same area without tension or therapeutic technique

    Device: sham kinesiotaping

Interventions

  • Devicekinesio taping

    The muscle technique consists of applying the tape without stretching it. Either the muscle or the skin is placed under stretch, but the tape itself is applied with no tension along its entire length. The base anchor is applied with the body segment in a neutral position; the target muscle is then stretched and the tape is laid over it. Finally, the segment is returned to the neutral position and the end anchor is applied. This technique is used to inhibit muscle tone. Once the tape has been applied, patients will be instructed to remove it on the fourth day. They may carry on with their normal daily activities and may get the tape wet when washing or showering. If the tape causes significant discomfort, patients may remove it early and must record this in their pain diary. If the tape comes off before the fourth day, patients must also record this in the diary.

  • Devicesham kinesiotaping

    The same tape placed on the same area without tension or therapeutic technique

06

What researchers measure

Primary outcomes

  1. Pain Intensity

    Pain intensity, measured using a Visual Analog Scale (VAS). Pain will be recorded before the first treatment session of each week. Since treatment consists of two physiotherapy sessions per week for four weeks, the VAS will be recorded at the start of sessions 1, 3, 5, and 8, the last of which corresponds to the final day of treatment. In addition, patients will complete a pain diary every day between treatment sessions.

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol

Time frame: After publication of main results of the study

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 763 non-industry interventional studies with no phase under Neck Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 35 months is above that.

Counting every sponsor, half of 772 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 9, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07926789
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Noemí Casaponsa
Contact
recerca@csapg.cat
0034938960025 ext. 43197

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion